SUMMARY The effects of placebo, propranolol and primidone were compared in 14 patients with essential tremor in a double blind, randomised, crossover study. Objective measures of tremor were obtained using an accelerometer with subsequent spectral analysis. Both propranolol (p < 0.01) and primidone (p < 0.01) gave significant improvement in tremor, but there was no significant difference in improvementVbetween these drugs. Patients withihigher dominant frequencies of tremor tended to respond to both drugs, while those with lower frequencies improved on one or other. There was no differential effect between the drugs with the frequency of tremor.
Benign essential tremor is a common condition characterised by tremor with postural and action components. Although benign in terms of its lack of effect on life expectancy, a small percentage of patients suffer serious disability as a result of tremor in the arms and hands, and a larger number find it a significant embarassment.' Propranolol and more recently primidone have been shown to be effective treatments,23 but they have not previously been compared in a controlled trial.
Patients and methods
Nineteen patients with a clinical diagnosis of essential tremor made in a neurology clinic gave informed consent and were included in the study. There were four females and 15 males, with a mean age of 58 years and a mean tremor duration of 16 years. Nine patients had a positive family history and 11 gave a history of improvement in the tremor with alcohol. Patients were excluded from the trial if any of the following were present: cardiac failure, asthma, peripheral vascular disease, diabetes mellitus, or pre-existing requirement for either propranolol or primidone.
Protocol
The study was 
Results
Nineteen patients entered the trial. One patient was excluded because the propranolol was probably subtherapeutic, one because of failure to tolerate propranolol, and three because of failure to tolerate primidone. Of the remaining 14 patients, the mean dominant tremor frequency was 6-4 Hz. The primidone levels ranged from 54 to 116 Amols/l, and the propranolol levels from 19 to 117 ng/ml. The resting pulse rate fell by a mean-of 11 beats per minute on propranolol compared to that on placebo.
When asked which treatment course they preferred, nine patients indicated that of primidone;, and five propranolol. One preferred propranolol even though he thought primidone more effective, because of slight drowsiness on the latter. Only two patients indicated the placebo course to be more effective that either one or other of the active drugs, and none preferred it to both.
Examples of "tremorgrams" and the spectrum plotted as square root of power against frequency 121-5 ± 23-3
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m ± sd = mean ± standard deviation across 24 recording epochs of tremor expressed as the square root of the power in the 3-13 Hz waveband for each patient. f = dominant frequency in power spectrum on baseline recording. * Reduction in tremor value on active drug compared to placebo significant at level p < 0-01 or better using Student's t test.
f Gorman, Cooper, Pocock, Campbell A comparison ofprinidone, propranolol, and placebo in essential tremor, using quantitative analysis 67 p> 0-10).
When the data from the average spectra were analysed in 1 Hz bands (table 2) , there were significant reductions in the 6-7 and 7-8 Hz bands with either drug; much of the power in the power spectrum was concentrated in this range (fig 2) . In addition there were reductions which reached statistical significance in the 9-10 Hz band for primidone and the 12-13 Hz band for propranolol. There was no significant change in the mean dominant frequency across the group on propranolol, but there was a fall in mean dominant frequency from 6-23 t 1*03 Hz on baseline measurement to 5 92 + 1-17 Hz on primidone, which was significant on Student's t test (t = 2-80, p < 0-02, n = 13. One patient was excluded because of lack of a clear peak frequency on primidone).
Those responding to both drugs had a significantly higher mean dominant frequency (7.35 Hz) than those responding to one or other (5.87 Hz), (p < 0.01). However the dominant frequency in individual patients was not associated with a selective advantage for one or other drug.
Discussion
The drug of choice in essential tremor is propranolol.4 However not all patients respond to this drug, and there are many patients, particularly in older age groups, in whom non-selective betaadrenoceptor blocking drugs are contraindicated owing to their bronchoconstrictor and negative inotrope effects. The advent of selective beta-2-adrenoceptor blockers may overcome some of these disadvantages and early studies in essential tremor have been encouraging.56 Primidone has also been shown to produce a dramatic improvement in some patients,37 although probably through a different mechanism involving a central oscillator rather than the peripheral mechanism proposed for betaadrenoceptor blockers. We have used spectral analysis to compare the response of a group of patients to these two drugs and hence to attempt to identify clinical guidelines for prescription of treatment.
When the tremor on a treatment was standardised as a percentage of the baseline tremor, the group showed an improvement both on propranolol at a dose of 40 mg three times daily and on primidone at a dose of 250 mg three times daily. This is in accordance with other reports,8-10 although a higher dose of propranolol has sometimes been required.' 12 We decided to use this dose after discussions with a number of neurologists, who were not happy to proceed directly to a propranolol dose of 240 mg daily for this indication. There was no difference between the tremor on propranolol and that on primidone. When the power spectra were reanalysed considering the power in consecutive bands of 1 Hz width, the benefit of both drugs was most obvious in the 6-8 Hz range but this may be a result of the relatively strong contribution from these frequencies to the power spectra. The changes which reach statistical significance in the other two bands occur at frequencies where there is little mean power but also little variation, and these are not thought to be of clinical significance. The absence of a significant change in peak frequency with propranolol is in agreement with previous reports.4 ' centrally, we were interested to see if patients with a lower dominant frequency were more likely to have a good response to primidone. This did not happen in our group, but it is notable that patients who had a significant response to both drugs tended to have a higher dominant frequency than those who responded only to one or other. Unfortunately our group of patients was too small to assess this trend in detail, but we feel that it is worth following up in future studies with a larger cohort of patients.
Ten patients showed a response to propranolol and nine responded to primidone, several with dramatic effect. There were frequent complaints of malaise, dizziness and unsteadiness on the first 62 5 mg of primidone, and two patients withdrew from the trial at this point. Primidone is known to cause more frequent side effects when given for essential tremor than in epilepsy, probably owing to concurrent anticonvulsant therapy in the latter. However after the first dose effects the drug was well tolerated, and when asked which of the double blind regimes they preferred, nine referred to primidone and four to propranolol. Data on age, family history, duration of tremor, response to alcohol, and clinical severity were analysed in an attempt to find clinical guidelines which would predict response to 68 primidone or propranolol. However in this group there were no consistent pointers.
We conclude that while propranolol remains the drug of choice, some patients who have contraindications to beta-adrenoreceptor antagonists and some who do not respond adequately to this treatment will benefit from primidone. A useful additive effect of the two drugs has been anecdotally reported,3 1 ' and this point requires clarification in further controlled trials.
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